Clin2
NCT06852625Worth exploringNot yet recruiting

Personalized immune cells to help highly sensitized kidney transplant patients

Kidney Transplant Rejection

Part of Immune system & allergy, Kidney & urinary clinical trials.

This early-phase trial tests a new therapy that uses your own immune cells to reduce your body's attack on a new kidney. It aims to help people who are highly sensitized (hard to match) get a transplant successfully.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
30 people
Ages
18 years to 65 years
Study type
Interventional

Who can take part

  • You must be between 18 and 65 years old.
  • You must be a candidate for a kidney transplant with a very high level of immune sensitivity (cPRA 90% or higher).
  • You must be able to have a procedure called leukapheresis (like a blood donation that collects white blood cells).
  • Women who can become pregnant must use birth control during the study.
  • You cannot have active infections like tuberculosis, hepatitis B or C, HIV, or current CMV/EBV infections.
  • You must not have had a heart attack in the last year or have serious blood clot or vascular problems.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05432765Not yet recruiting
Personalized medicine for kidney transplant recipients

This study tests a personalized approach to managing immunosuppression after a kidney transplant to improve long-term kidney function. It may help find the right dose of tacrolimus for each person.

Gainesville, Florida
NCT07539857Recruiting· Phase 2
Belimumab to help highly sensitized kidney transplant candidates

This study tests whether a medication called belimumab can help people who are highly sensitized (their immune system has many antibodies against donor organs) become eligible for kidney transplant by improving how doctors understand their antibody patterns. The goal is to help these patients access transplants more easily.

Leiden
NCT07607197Recruiting· Phase 1/Phase 2
Immune Reset to Help Highly Sensitized Kidney Transplant Patients

This study tests whether a special immune-resetting treatment can help patients who have developed too many antibodies against donor kidneys get access to a compatible kidney transplant. The treatment uses chemotherapy and stem cell transplantation to 'reset' your immune system so it stops rejecting potential donor kidneys.

Barcelona, Catalonia
NCT06809075Recruiting
Stem cell therapy to help highly sensitized patients get a kidney transplant

This trial tests if a special stem cell treatment (using your own stem cells) can reset your immune system so you can accept a kidney from a deceased donor, even if you have very high antibody levels that make it hard to find a match. It's for people who have been waiting a long time and haven't had a transplant offer.

Barcelona
NCT07350837Recruiting· Early Phase 1
CAR-T therapy for highly sensitized kidney transplant patients

This trial tests a new CAR-T therapy that targets immune cells to reduce harmful antibodies in highly sensitized kidney transplant candidates. The goal is to help your body accept a kidney from a donor that would otherwise be rejected.

Wuhan, Hubei
NCT05753930Recruiting· Phase 2
New medicine to help highly sensitised children receive kidney transplants

This trial tests a new medicine called imlifidase that quickly removes harmful antibodies from the blood. It is given to children before a kidney transplant to make the donated kidney more likely to be accepted, especially when standard desensitisation methods have failed.

Helsinki

Hear when a new Kidney Transplant Rejection trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.